Gene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.
New CEO at Ipsen
AppointmentsDavid Loew, formerly executive vice president of Sanofi Pasteur, was appointed as CEO of French Ipsen Pharma SA at the beginning of July.
Antimicrobial resistance This is not the time to wait. This is the time to act.
Sponsored PublicationsEmperor Nero, reportedly, fiddled as Rome burned in 64 A.D., much like society for a long time ignored and repressed the pending crisis of antimicrobial resistance (AMR).
Abbvie and Genmab team up in oncology
Latest NewsAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics signs US$1.2bn deal with Eli Lilly
Latest NewsEvox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Calliditas Therapeutics raise US$90m in Nasdaq IPO
Latest NewsSwedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
New Chief Business Officer for MaaT Pharma
AppointmentsDr Savita Bernal joined the Lyon-based MaaT Pharma as new Chief Business Officer.
Hyloris Pharmaceuticals prepared to go public
Latest NewsBelgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera bags US$55m in Series B round
Latest NewsNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
Latest NewsAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
ELEVECTA® Unlocking The Full Potential of Gene Therapy
Sponsored PublicationsGene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.